We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Ipsogen Launches MapQuant Dx™ Genomic Grade Test to Analyze Chemotherapy Results

Want a FREE PDF version of this news story?

Complete the form below and we will email you a PDF version of "Ipsogen Launches MapQuant Dx™ Genomic Grade Test to Analyze Chemotherapy Results"

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.
Read time:

Ipsogen SA has announced that it is entering the breast cancer diagnostic market with the European launch of MapQuant Dx™ Genomic Grade. MapQuant Dx™ Genomic Grade is the very first molecular diagnostic test to measure tumor grade, a consensus indicator of tumor proliferation, risk of metastasis and response to chemotherapy.

Histological tumor grading is considered a decision factor in most national and international guidelines to breast cancer treatment. While it is generally recommended to treat high-grade "grade 3" breast carcinoma with chemotherapy because they are chemosensitive and will often recur otherwise. By contrast, most low-grade "grade 1" tumors should not be treated with chemotherapy because they have a good prognosis and are often chemo-insensitive.

A key clinical issue is how to treat the 50% of breast cancers tested today as uncertain/intermediate "grade 2" by current methods - based on the visual examination of tumor sections under the microscope.

MapQuant Dx™ Genomic Grade test directly measures the expression of the 97 genes that best characterize high-grade vs. low-grade tumors. It can resolve these "grade 2" tumors into either "grade 1" or "grade 3" tumors in 80 % of cases.

MapQuant Dx™ Genomic Grade test is especially useful when tumor grade information can be decisive for prescribing a chemotherapy. According to most guidelines, this is the case for hormone-sensitive (ER+) node-negative (N-) invasive breast carcinoma.

"In these patients, most grade 2 tumors are treated by chemotherapy and hormonotherapy. It is expected that MapQuant Dx™ Genomic Grade test downgrades 70% of grade 2 tumors to grade 1. This would represent about 50,000 spared chemotherapies in Europe and USA annually," said Dr. Jean-Marc Le Doussal, Director of the Breast Cancer Program at Ipsogen.

"MapQuant Dx™ Genomic Grade demonstrates our commitment to address clinicians' needs by translating the genomic profile of each tumor into reliable, intelligible and decisive information for pathologists, oncologists and patients," said Vincent Fert, President and CEO of Ipsogen.